Systemic arterial hypertension: treatment with Integrative and Complementary Health Practices Hipertensão arterial sistêmica: tratamento com práticas integrativas e complementares de saúde Hipertensión arterial sistémica: tratamiento con prácticas de salud integradoras y complementarias

Systemic Arterial Hypertension (SAH) can generate complications such as stroke, myocardial infarction, kidney disease, arteriosclerosis, loss of vision, erectile dysfunction and cognitive dysfunction. Among people who know they suffer from hypertension, 50% use medication and of those only 45% have their blood pressure kept under control. SAH is a multifactorial clinical condition characterized by elevated and sustained blood pressure levels (BP, where systolic BP ≥ 140 mmHg and diastolic BP ≥ 90 mmHg). Faced with sparse investigative studies on the causes of SAH in individuals, the dictates of the pharmaceutical industry and the use of in vitro or inconclusive clinical studies, this paper presents the state of the art about the treatment of SAH based on a multifaceted view, including aspects about the physiology of SAH, food and PANC as alternatives for the prevention and control of SAH, as well as an approach on the importance of scientific rigor in the manufacture of medicines.

After the hematosis process (gas exchange that occurs in the lungs through venous and arterial blood) the arterial blood returns from the lungs to the heart (LA) through the two pulmonary veins. This characterizes the moment of atrial diastole. Crossing the bicuspid (mitral) valve, the blood volume reaches the LV and travels through the aorta (systemic circulation or large circulation) and coronary arteries (coronary circulation) to the whole organism, giving rise to maximum pressure or systolic blood pressure [SBP]) during the blood passage, and a minimum pressure or diastolic blood pressure (DBP) coming from the return of the vessel to its initial diameter. This allows the blood to continue its course towards the blood capillaries (Savioli & Savioli, 2019).
Blood pressure changes with everyday situations such as moments of anxiety, physical activity, feelings of pain, medical care and so on. Most of the time, hypertension is asymptomatic or the symptoms are common to some other disease (headache, dizziness, malaise). For this reason, it is called a "silent killer disease". Monitoring BP levels is a lifelong task for hypertensive patients.
Blood pressure is measured using an aneroid sphygmomanometer (without mercury and with a diaphragm), which must be periodically tested and calibrated. This calibration can be done using digital devices that must be used with great care, as they are susceptible to many errors. Monitoring can also take place with instruments such as ABPM (Ambulatory Blood Pressure Monitoring) or HBPM (Residential Blood Pressure Measurement), blood of 10kg is associated with an average reduction of 6.0 mmHg in systolic BP and 4.0 mmHg in diastolic BP.
Savioli & Savioli (2019) consider that any excess body fat is harmful to health in general and weight gain is directly related to the increase in blood pressure levels in both adults and children. Visceral fat, located more deeply around important organs such as the liver, pancreas and kidneys, is an even greater risk factor than subcutaneous fat. Adipose tissue is considered an endocrine organ, releasing a series of hormones into the bloodstream.
In addition, the authors cite that excess fat is pro-inflammatory because it eliminates small proteins (cytokines), such as Interleukin-6 (IL-6), which stimulate the production of other proteins of the acute phase of inflammation and increase the secretion of triglycerides by the liver, contributing to hypertriglyceridemia associated with visceral obesity.
Excessive alcohol consumption also contributes significantly to the uncontrolled BP.
The daily consumption of more than two drinks (about 24 g / day) is associated with an increase in blood pressure levels (Toledo et al., 2020). The association between serum uric acid and cardiovascular disease such as hypertension, metabolic syndrome and coronary and cerebral vascular diseases has been reported in several epidemiological studies. According to Finally, regardless of whether or not there is a possible direction of scientific research sponsored by the market, we cannot ignore the fact that the standardization proposed by GMPs associated with the consolidation of inspection by regulatory agencies, contributes to a fairer competitiveness even considering different manufacturers.

Conclusion
The health industry subjects individuals to treatment for the consequences of hypertension, neglecting the causes that led the body to adapt to cardiac output and vascular resistance. Thus, the need to change eating habits, smoking outcome, weight control, quality of sleep, reduced consumption of alcoholic beverages and physical exercise is little appreciated.
To reverse this dynamic, health professionals need to understand the patient as a human being, enabling, among other integrative measures, using PANC to treat causes within the understanding of the current multiplicity that requires the interaction of views from different areas of knowledge and different social references (multifaceted view).
In addition, in the process of manufacturing and developing new drugs, there are specific GMP criteria, strictly following the different pre-clinical and clinical phases. In the preclinical phases, the drugs undergo preliminary tests on animals, the most common being rats and dogs because they are easy to access and have a low cost, in addition to presenting low toxicity, among other characteristics. Once these tests are approved in guinea pigs, the phase called the clinic begins, where the drug has its effectiveness tested from its use in humans, initially in a small group (PHASE I), and then evolve in large groups of people.
(PHASES II and III). In all these phases, criteria such as safety, quality and efficacy of the Development, v. 9, n. 11, e45991110156, 2020 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v9i11.10156 20 drug are verified and it can take years before a new drug is then made available for consumption on the market, which costs manufacturers some good millions of dollars.
All of this development opens up a new range of discussions and questions about the need to use guinea pigs, whether animal or human, as well as the effectiveness of responses throughout this journey. Although the regulation requires ethical rigor, it is still questioned, whether by animal protection agencies or by civil society, which sees in this process a vulnerability of people, especially the least favored. If, on the one hand, there are advocates that this process is necessary because there are no techniques to replace it, on the other are the arguments that technological advances need to make it possible to investigate the effect of substances on the human body without the use of a guinea pig. This discussion is far from over and needs to be further investigated by scientists in partnership with civil society and regulatory bodies.
Finally, as a proposal for future work in the study of SAH, the importance and the result of understanding the endocrine system in the control of hypertension can also be raised and evaluated. In contrast, discuss the problems in drug interactions with angiotensinconverting enzyme inhibitors, angiotensin receptor blockers or direct renin inhibitors. Health technologies must be at the service of society as an alternative for validating treatments and clinical research, including pharmacological and non-pharmacological, safeguarding life.